Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Anlotinib combined with nab-paclitaxel and cisplatin as neoadjuvant treatment (NAT) for esophageal squamous cell carcinoma (ESCC): Update results of a single-arm, phase Ⅱ clinical trial.
Authors
Yan-Feng Zhang
Anyang Tumor Hospital, Anyang, China;
Yan-Feng Zhang , Xiao-Bing Li , Yong-Gui Hong , Xiao-Ming Li , Wei-Min Liang , Zhi-Xin Zheng , Guang-Yi Yang , Yan-Yan Wen , Heng Cao , Wei-Long Wu , Wen-Zhong Su
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 366)
DOI
10.1200/JCO.2023.41.4_suppl.366
Abstract #
366
Poster Bd #
F7
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
ALTER-UC-007: A prospective phase 2 study of anlotinib with gemcitabine and cisplatin or anlotinib with penpulimab as perioperative treatment for patients with muscle-invasive urothelial carcinoma (MIUC).
First Author: Hailiang Zhang
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Anlotinib combined with paclitaxel and cisplatin as neoadjuvant treatment for esophageal squamous cell carcinoma (ESCC).
First Author: GONGQIAN JIANG
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Safety and short-term efficacy of neoadjuvant FLOT therapy in patients with resectable esophageal squamous cell carcinoma.
First Author: Yuri Yoshinami
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Short-term safety of adjuvant nivolumab therapy after neoadjuvant docetaxel plus cisplatin and 5-FU therapy for locally advanced esophageal squamous cell carcinoma.
First Author: Toshiharu Hirose